The largest database of trusted experimental protocols

Florbetapir

Florbetapir is a positron emission tomography (PET) imaging agent used to detect the presence of beta-amyloid plaques in the brain.
It is utilized in the diagnosis and monitoring of Alzheimer's disease and other neurodegenerative disorders.
Florbetapir binds to beta-amyloid proteins, allowing visualization of these hallmark pathological features associated with cognitive impairment.
Researchers leveraging PubCompare.ai can easily identify the most accurate and reproducible protocols for Florbetapir imaging, acheving reliable, data-driven results for their research.

Most cited protocols related to «Florbetapir»

PiB and florbetapir image data were analyzed using 2 processing streams. The PET-template analysis method was described in a separate study (10 (link)). This method was applied to the raw and unsmoothed datasets. Briefly, image data were spatially normalized to standard atlas coordinates in Talairach space using statistical parametric mapping software (11 ). Mean tracer retention was calculated for 6 predefined target cortical regions of interest (medial orbital frontal, temporal, parietal, anterior cingulate, posterior cingulate, and precuneus) that resulted from a statistical contrast of AD patients and cognitively normal subjects (1 (link)).
The Freesurfer method for quantifying cortical Aβ was applied to the unsmoothed and smoothed datasets. This method was described in detail elsewhere (2 (link),12 (link)) and online (13 ). Structural 1.5-T or 3-T MRI scans (T1-weighted images) were used to define cortical regions of interest and the cerebellar reference region. In general, 2 structural MRI scans were acquired at each visit across several years of follow-up, with the result that several MR images were available for each subject. For processing the PiB images, we chose the T1 scans acquired concurrently with (or closest in time to) the first PiB scan; and for the florbetapir processing, we chose the T1 scans acquired concurrently with (or closest in time to) the florbetapir scan. Structural MR images were segmented and parceled into individual cortical regions with Freesurfer (version 4.5.0; surfer.nmr.mgh.harvard.edu/) and subsequently used to extract mean PiB and florbetapir cortical retention ratios from gray matter within lateral and medial frontal, anterior and posterior cingulate, lateral parietal, and lateral temporal regions.
To examine several reference regions, the unscaled cortical means for each analysis method were divided by mean retention in the following 3 reference regions: brain stem–pons, whole cerebellum (white and gray matter), and cerebellar gray matter, yielding 3 cortical retention ratios for each preprocessing method. Because Freesurfer creates a brain stem, but not pons, region as part of its automated processing stream, the brain stem was used for the Free-surfer processing analysis method and the pons was used for the PET-template processing method.
To summarize, for each of 3 PET sessions (2 PiB scans and 1 florbetapir scan), every subject had cortical retention ratios for 2 levels of processing and 2 analysis methods (raw and unsmoothed for the PET-template method and unsmoothed and smoothed for the Freesurfer method), using 3 reference regions (brain stem–pons, whole cerebellum, cerebellar gray matter), resulting in 36 mean cortical retention ratios per subject that were compared in subsequent statistical analyses.
Publication 2012
Brain Stem Cerebellar Gray Matter Cerebellum Cortex, Cerebral florbetapir Gray Matter Gyrus, Anterior Cingulate MRI Scans Patients Pons Posterior Cingulate Cortex Precuneus Radionuclide Imaging Retention (Psychology) Temporal Lobe
ADNI PET image data were acquired as described online (adni.loni.ucla.edu/about-data-samples/image-data/), and processed by our laboratory as described online (adni.loni.ucla.edu/research/pet-post-processing/) and summarized briefly below.
Florbetapir image data were acquired 50 to 70 minutes postinjection, and images were averaged, spatially aligned, interpolated to a standard voxel size, and smoothed to a common resolution of 8mm full width at half maximum.
For quantification of florbetapir, we used 1 or, in most cases, 2 structural 1.5T or 3T MRI scans (magnetization-prepared rapid acquisition gradient echo [MPRAGE]) acquired concurrently with the florbetapir scan to define cortical regions of interest and the cerebellar reference region. MPRAGE scans within 1 year of the florbetapir scan were available for approximately 80% of subjects. For the remaining subjects, we used the MPRAGE that was closest in time to the florbetapir scan (average MRI–florbetapir interval = 1.9 ± 0.8 years). MPRAGE images were segmented and parcellated into individual cortical regions with Freesurfer version 4.5.0 (surfer.nmr.mgh.harvard.edu/), which was used to extract mean florbetapir uptake from gray matter within lateral and medial frontal, anterior, and posterior cingulate, lateral parietal, and lateral temporal regions relative to uptake in the whole cerebellum (white and gray matter). This summary measure was used as the florbetapir cortical mean for each subject.
Publication 2012
Cerebellum Cortex, Cerebral ECHO protocol florbetapir Gray Matter MRI Scans Posterior Cingulate Cortex Radionuclide Imaging Temporal Lobe
Participants were imaged at 23 sites using clinical PET and PET/computed tomographic scanners. Each participant underwent a 10-minute PET scan, which began 50 minutes after receiving an intravenous bolus of 370 MBq (10 mCi) florbetapir F 18. Images were acquired with a 128 × 128 matrix (zoom × 2) and were reconstructed using iterative or row action maximization likelihood algorithms.
Florbetapir-PET images were assessed visually using a semiquantitative score ranging from 0 (no amyloid) to 4 (high levels of cortical amyloid) by 3 board-certified nuclear medicine physicians who were not involved in any other aspects of the study. The only experience these physicians had with florbetapir-PET imaging occurred during a half-day training session. The median rating of the readers served as a primary outcome variable. Readers were blinded to clinical, demographic, and neuropathological information and viewed and rated images under the supervision and at the facility of the imaging core laboratory (ImageMetrix, a division of the American College of Radiology, Philadelphia, Pennsylvania). The initial 6 postmortem evaluations were rated by 4 readers and the median rating of the 4 raters served as the primary outcome variable for these 6 participants.
For the younger control cohort, the PET images were mixed in random order with 40 images from the autopsy cohort that had a median visual read score between 2 and 4 (inclusive). To remove image recognition bias, these images were rated as amyloid positive or negative at ImageMetrix by a different group of 3 external readers. The majority rating was used as the primary outcome variable for this analysis.
A semiautomated quantitative analysis of the ratio of cortical to cerebellar signal (SUVr) also was performed for florbetapir-PET images from all study participants. The images were first normalized to a standard template in the Talairach space and then the SUVrs were calculated for the 6 predefined cortical regions of interest (frontal, temporal, parietal, anterior cingulate, posterior cingulate, and precuneus). The whole cerebellum was used as the reference region.
Publication 2011
Amyloid Proteins Autopsy CAT SCANNERS X RAY Cerebellum Cortex, Cerebral florbetapir florbetapir F 18 Gyrus, Anterior Cingulate Inclusion Bodies Physicians Posterior Cingulate Cortex Precuneus Radiography Radionuclide Imaging Supervision
Our study population was 426 ADNI participants with an available florbetapir and MRI scan as of November 2011 (126 normal, 162 early MCI, 85 LMCI, 53 AD); 417 of these participants also had an FDG-PET scan acquired approximately concurrently with the florbetapir scan (average time between FDG-PET and florbetapir, <1 week). Approximately ⅔ of the total sample were newly enrolled subjects who had no longitudinal follow-up, whereas approximately ⅓ were continuing normal (n = 76) and LMCI (n = 81) participants from ADNI 1 who were followed for an average of about 4 years prior to their florbetapir scans.
Full inclusion/exclusion criteria are described in detail at www.adni-info.org. Briefly, all subjects were between the ages of 55 and 90 years, had completed at least 6 years of education, were fluent in Spanish or English, and were free of any other significant neurologic diseases. LMCI participants had a subjective memory complaint, a Clinical Dementia Rating (CDR) of 0.5, and were classified as single- or multidomain amnestic.14 The EMCI group differed from LMCI only based on education-adjusted scores for the delayed paragraph recall subscore on the Wechsler Memory Scale–Revised Logical Memory II such that EMCI subjects were intermediate between normal subjects and LMCI. Normal subjects had CDR scores of 0, and patients with AD met standard diagnostic criteria.15 (link)The ADAS-cog16 (link) was used in our cross-sectional analyses and as the primary outcome variable in our longitudinal analyses; total score ranges from 0 to 70, with a higher score indicating poorer cognitive function. We also assessed changes in diagnostic status (eg, remaining LMCI or converting to AD), which was determined at individual testing sites.
Apolipoprotein E (APOE) genotypes were determined with blood samples for all except 2 EMCI subjects.
Publication 2012
Apolipoproteins E BLOOD Cognition Diagnosis florbetapir Genotype Hispanic or Latino Memory Mental Recall MRI Scans Nervous System Disorder Patients Positron-Emission Tomography Radionuclide Imaging
Florbetapir synthesis and image acquisition details are described in detail elsewhere ((7 (link)), http://adni-info.org). Briefly, florbetapir images consisted of 4 × 5 min frames acquired at 50–70 min after injection, which were realigned, averaged, resliced to a common voxel size (1.5 mm3), and smoothed to a common resolution of 8 mm3 in full width at half maximum.
Structural T1 images acquired concurrently with the baseline florbetapir images were used as a structural template to define cortical regions of interest and reference regions in native space for each subject using Freesurfer (version 4.5.0; surfer.nmr.mgh.harvard.edu) as described previously (7 (link),21 (link),22 (link)).
Baseline and follow-up florbetapir scans for each subject were coregistered to baseline structural MR scans, which were subsequently used to extract weighted cortical retention means (SUVRs) from gray matter within 4 large cortical regions of interest (frontal, cingulate, parietal, and temporal cortices) that were averaged to create an SUVR as described in greater detail in recent studies (7 (link),21 (link)) and online (23 ).
Publication 2015
Anabolism Cortex, Cerebral florbetapir Gray Matter Radionuclide Imaging Reading Frames Retention (Psychology) Temporal Lobe

Most recents protocols related to «Florbetapir»

The present study employed AV-45 PET to quantify Aβ deposition through the collection of 4 × 5-minute frames from 50 to 70 minutes after the injection of approximately 15 mCi of tracer. All scans underwent quality control checks, including assessing counts, field-of-view, and subject movement. Subsequently, the standardized SUVR images were created by applying a series of processing steps, which included realigning and averaging the 50–70 min post-injection frames, processing the images to a standard orientation and voxel size, smoothing to a common resolution of 8 mm FWHM, and normalizing the intensity. To achieve normalization, the global cortical mean standardized uptake value ratio (SUVR), as well as the regional cortical and subcortical SUVR, were calculated using two different normalization methods(25 (link), 26 (link)). Specifically, the global cortical mean SUVR was calculated relative to a composite reference region consisting of the whole cerebellum, brainstem/pons, and subcortical white matter(20 (link)), whereas the regional cortical and subcortical SUVR were intensity normalized to the cerebellum. Finally, regional SUVR was extracted for the standardized SUVR images using regions of interest (ROI) derived from the FreeSurfer software packages(27 (link)).
Full text: Click here
Publication Preprint 2024
Simultaneous 18F-Florbetapir PET/MR scans were performed on an integrated PET/MR system (uPMR 790, United-Imaging Healthcare, Shanghai) equipped with 12-channel phase-array body surface coil. A segmented MR-based attenuation correction map for ungated PET was generated by using the same respiration-gated Dixon sequence [16 (link)]. PET was started immediately after an intravenous bolus injection of 18F-Florbetapir of 9.04 ± 1.89 mCi (mean ± SD, hereafter).
Full text: Click here
Publication 2024
The uptake of 18F-Florbetapir in the left ventricle (LV) myocardium was visually performed using static PET images from 0 to 60 min post-injection (p.i.). A total of 18 regions of interest (ROIs) including 17 segments of the LV were manually oriented and adjusted, and then automatically segmented by using the PCARD model in PMOD (version 4.2, PMOD Technologies LLC., Zurich, Switzerland). The ROIs delineation of the left and right kidney were manually drawn based on the first 5-min mean images. Time activity curves (TACs) were obtained by applying ROIs to 0 and 60 min dynamic images for kinetic analysis. The ROIs were also applied directly to parametric images for the estimation of DVR and R1.
Full text: Click here
Publication 2024
All participants underwent 18F‐florbetapir PET as well as 3.0T multimodal brain MRI. The interval between the two imaging examinations did not exceed 1 month. 18F‐florbetapir PET was scanned using Biograph 128 mCT, Siemens, Germany and uPMR790 TOF, Untied Imaging, China. Intravenous injection of 18F‐florbetapir 7.4 MBq/kg was administered according to the subject's body mass, and brain PET/CT visualization was performed after 50 min of quiet rest.10‐s low‐dose head CT scan at one bed position.20‐min brain PET scan in 3D mode; PET image reconstruction using filtered inverse projection; MR scan using a 3.0T Siemens Prisma MR scanner, Germany; T1 structural imaging using Magnetization Prepared Rapid Gradient Echo imaging (MPRAGE).
Postacquisition images were visually assessed using FBP reconstruction. Reconstructed 18F‐florbetapir PET images were visually analyzed by an intermediate (W.‐Y.W.) and a senior PET diagnostician (J.‐J.G.). In the case of disagreement, a third senior diagnostician (F.X.or C.‐T.Z.) made the judgment. Based on the distribution of cortical Aβ deposits, the diagnostic results were categorized as positive and negative (Figure S2).
27 ,
28 (link)
Publication 2024
[18 F]Florbetapir PET data were quantified using the standardized uptake value ratio (SUVr), with the cerebellum grey matter serving as the reference region. The global cortical Aβ burden was computed as the mean SUVr in cortical area, including posterior cingulate, precuneus, frontal, lateral parietal, lateral temporal, medial temporal, and occipital regions. The positive 18F-florbetapir PET images were defined through visual rating following the guidelines for interpreting amyloid PET42 (link). Three physicians independently assessed all amyloid PET images, and results were determined based on a consensus, with agreement among at least two physicians. Additional details on the acquisition and preprocessing of [18 F]Florbetapir PET neuroimaging are provided in the supplementary information.
Full text: Click here
Publication 2024

Top products related to «Florbetapir»

Sourced in Germany
The ECAT HR PET scanner is a positron emission tomography (PET) device manufactured by Siemens. It is designed for high-resolution imaging of the human body. The scanner uses advanced technology to detect and measure the distribution of radioactive tracer substances in the body, providing detailed information about its internal structure and function.
Sourced in Germany, United States
The Biograph mMR is a positron emission tomography (PET) and magnetic resonance imaging (MRI) system manufactured by Siemens. It integrates PET and MRI technologies to provide simultaneous imaging of the body. The Biograph mMR enables the acquisition of high-quality PET and MRI data in a single examination.
Sourced in United States, Germany
The Ingenuity TF PET/CT is a medical imaging system developed by Philips. It combines positron emission tomography (PET) and computed tomography (CT) technologies to provide detailed images of the human body. The system is designed to assist healthcare professionals in the diagnosis and management of various medical conditions.
Sourced in Germany
The Biograph mCT Flow PET/CT is a diagnostic imaging system that combines positron emission tomography (PET) and computed tomography (CT) technologies. It is designed to capture high-quality images for medical analysis and evaluation.
Sourced in Germany, United States
The Biograph mMR scanner is a medical imaging device developed by Siemens. It combines magnetic resonance imaging (MRI) and positron emission tomography (PET) technologies in a single system, enabling simultaneous acquisition of both anatomical and molecular data. The core function of the Biograph mMR scanner is to provide healthcare professionals with integrated diagnostic information for a wide range of clinical applications.
Sourced in Germany
The Biograph 40 PET/CT scanner is a medical imaging device that combines positron emission tomography (PET) and computed tomography (CT) technologies. The core function of the Biograph 40 is to acquire and integrate high-quality PET and CT images, providing healthcare professionals with comprehensive diagnostic information.
Sourced in Germany, United States
The Biograph 64 is a medical imaging device produced by Siemens. It is a hybrid system that combines positron emission tomography (PET) and computed tomography (CT) technologies. The Biograph 64 is designed to acquire high-quality images for diagnostic and research purposes.
18F-Florbetapir is a radioactive tracer used in positron emission tomography (PET) imaging. It is designed to bind to beta-amyloid deposits in the brain, which are associated with Alzheimer's disease. The primary function of 18F-Florbetapir is to aid in the detection and assessment of beta-amyloid pathology in the brain.
Sourced in United States
The Discovery PET/CT 710 is a medical imaging system that combines positron emission tomography (PET) and computed tomography (CT) technologies. It is designed to capture high-quality images of the human body for diagnostic and treatment planning purposes.

More about "Florbetapir"

Florbetapir is a powerful positron emission tomography (PET) imaging agent used to detect the presence of beta-amyloid plaques in the brain.
This cutting-edge technology is crucial for the diagnosis and monitoring of Alzheimer's disease and other neurodegenerative disorders.
Florbetapir works by binding to the beta-amyloid proteins, allowing researchers and clinicians to visualize these hallmark pathological features associated with cognitive impairment.
This enables them to gain valuable insights into the progression of the disease and make more informed decisions about treatment options.
Researchers leveraging advanced PET imaging platforms, such as the ECAT HR PET scanner, Biograph mMR, Ingenuity TF PET/CT, Biograph mCT Flow PET/CT, and Biograph 40 PET/CT scanner, can utilize PubCompare.ai to identify the most accurate and reproducible protocols for Florbetapir imaging.
This powerful AI-powered platform helps researchers locate the best Florbetapir protocols and products from scientific literature, pre-prints, and patents, ensuring reliable and data-driven results for their research.
The Discovery PET/CT 710 and Biograph 64 are also popular PET imaging systems that can be used in conjuction with 18F-Florbetapir to visualize and quantify beta-amyloid deposition in the brain.
By leveraging these cutting-edge technologies and the insights gained from PubCompare.ai, researchers can acheive new breakthroughs in the understanding and treatment of Alzheimer's disease and other neurodegenerative conditions.